Alcohol Use Disorder Pipeline Report 2026 Highlights 30+ Companies and 30+ Therapies Shaping Future Treatment Trends, analyses DelveInsight

Alcohol Use Disorder Pipeline

According to DelveInsight’s evaluation, the global Alcohol Use Disorder (AUD) pipeline includes more than 30 prominent companies actively engaged in the development of over 30 innovative treatment therapies. The report provides detailed analysis of clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and recent advancements.

The “Alcohol Use Disorder Pipeline Insight, 2026” report by DelveInsight presents an extensive overview of the current clinical development landscape along with future growth opportunities within the Alcohol Use Disorder market.

The Alcohol Use Disorder pipeline report delivers a comprehensive clinical and commercial evaluation of pipeline candidates, ranging from preclinical stages to marketed products. It also offers detailed drug profiles, including mechanism of action, clinical trial progress, regulatory approvals (if applicable), and development activities such as technologies used, partnerships, mergers and acquisitions, funding, designations, and other relevant product information.

Download a free sample PDF report to explore detailed insights into the Alcohol Use Disorder pipeline therapeutic landscape @ https://www.delveinsight.com/report-store/alcohol-use-disorder-pipeline-insight

xKey Highlights from the Alcohol Use Disorder Pipeline Report

• Organizations worldwide are actively focused on advancing novel therapies for Alcohol Use Disorder, achieving notable progress over time. Leading companies such as Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others are driving innovation in this space.
• Emerging therapies including Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others are anticipated to significantly influence the future Alcohol Use Disorder market.
• In February 2025, a Phase II placebo-controlled study indicated that a once-weekly dose of semaglutide could potentially reduce alcohol cravings and overall consumption among individuals with AUD. Conducted by the University of North Carolina at Chapel Hill (NCT05520775), the nine-week trial reported that nearly 40% of participants receiving semaglutide experienced a meaningful decrease in alcohol cravings.
• In November 2024, Adial Pharmaceuticals secured a patent from the United States Patent and Trademark Office, broadening protection across a wider range of genotype combinations identified through its proprietary genetic testing platform. This supports the targeted use of its lead investigational drug, AD04, for AUD treatment. During the same period, the company also announced encouraging topline pharmacokinetic (PK) results for AD04, which are expected to guide the design of its upcoming Phase III clinical trial.
• In August 2024, Adial Pharmaceuticals entered into a partnership with Boudicca to enhance the development of technical and regulatory strategies for its companion diagnostic genetic testing solution.
• In July 2024, the US FDA approved the IND application for CMND-100 oral capsules, enabling the initiation of a Phase I/IIa clinical trial in the United States for AUD. Additionally, Clearmind Medicine formed a strategic collaboration with JS First Sdn. Bhd. to identify global manufacturing and distribution partners for its MEAI-based alcohol substitute beverages, facilitating its global expansion strategy. Earlier, in June 2024, Adial Pharmaceuticals published findings from its Phase III ONWARD study in the European Journal of Internal Medicine.

Alcohol Use Disorder Overview

Alcohol Use Disorder (AUD) is a chronic, relapsing condition marked by an impaired ability to regulate alcohol consumption despite harmful effects on physical health, mental well-being, and social life. It exists on a spectrum, ranging from mild to severe forms.

Request for free sample report now @ https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight

Route of Administration

The report evaluates pipeline therapies based on their routes of administration, categorizing them into:

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Pipeline products are further segmented by molecule type, including:

• Gene therapies
• Small molecules
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Product Type Analysis

The report provides detailed therapeutic assessment across:

• Alcohol Use Disorder analysis by product type
• Alcohol Use Disorder segmentation by development stage and product type
• Assessment by route of administration
• Stage-wise evaluation based on administration route
• Analysis by molecule type
• Stage-wise segmentation based on molecule type

DelveInsight’s report covers approximately 5+ pipeline products across various stages of development, including:

• Late-stage (Phase III) candidates
• Mid-stage (Phase II) therapies
• Early-stage (Phase I) products
• Preclinical and discovery-stage compounds
• Discontinued and inactive candidates

Further details on Alcohol Use Disorder pipeline products are available in the report. Download the report to gain deeper insights into emerging therapies @ https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight

Key Companies in the Alcohol Use Disorder Therapeutics Market

Major players involved in developing AUD treatments include Alkermes, Teva Pharmaceutical Industries Ltd., BioCorRx, Inc., Adial Pharmaceuticals, Addex Therapeutics, Kinnov Therapeutics, Opiant Pharmaceuticals, Ethypharm, Omeros Corporation, Montisera Ltd., and others.

Emerging Drugs in the Alcohol Use Disorder Pipeline

• Pear-009 – Pear Therapeutics
• CYB003 – Cybin
• Nezavist – Lohocla Research
• BXCL501 – BioXcel Therapeutics
• PT150 – Pop Test Oncology
• DCR-AUD – Dicerna Pharmaceuticals
• ASP8062 – Astellas Pharma
• KT 110 – Kinnov Therapeutics
• Ibudilast – MediciNova
• AD04 – Adial Pharmaceuticals

Alcohol Use Disorder Pipeline Analysis

The report offers valuable insights into:

• Companies actively developing AUD therapies along with their respective pipelines
• Segmentation of therapeutic candidates into early, mid, and late development stages
• Active and inactive (discontinued or dormant) pipeline projects
• Drug classification based on development stage, route of administration, target receptor, therapy type (monotherapy/combination), mechanism of action, and molecular category
• Comprehensive analysis of partnerships, licensing agreements, and funding activities shaping future market growth

The report is compiled using data sourced from proprietary databases, company and academic websites, clinical trial registries, conferences, SEC filings, investor presentations, press releases, and other reliable third-party sources.

Download the sample PDF report to explore detailed insights into Alcohol Use Disorder therapies and drug development @ https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight

Alcohol Use Disorder Pipeline Market Drivers

• Growing awareness regarding Alcohol Use Disorder
• Increasing investment in research and development
• Strategic initiatives by key market players

Alcohol Use Disorder Pipeline Market Challenges

• Low treatment adoption rates
• Adverse effects associated with existing therapies

Scope of the Alcohol Use Disorder Pipeline Report

• Coverage: Global
• Key Companies: Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others
• Key Therapies: Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others
• Therapeutic Assessment: Marketed and emerging therapies
• Market Dynamics: Drivers and barriers

Request a sample PDF report for detailed insights into the Alcohol Use Disorder pipeline and clinical trial landscape @ https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight

Table of Contents

1. Alcohol Use Disorder Report Introduction
2. Executive Summary
3. Disease Overview
4. Analytical Perspective and Commercial Assessment
5. Pipeline Therapeutics
6. Late-Stage Products (Phase II/III)
7. Mid-Stage Products (Phase II)
8. Early-Stage Products (Phase I)
9. Preclinical Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaboration and Licensing Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Outlook and Conclusion
18. Analyst Views
19. Appendix
20. About DelveInsight

Note: The Table of Contents is indicative and may vary. Refer to the sample report for complete details.

About DelveInsight

DelveInsight is a leading business consulting and market research firm specializing in the life sciences sector. The company supports pharmaceutical organizations with comprehensive, end-to-end solutions designed to enhance performance. Its healthcare consulting services enable clients to perform in-depth market analysis, accelerate growth, and effectively address industry challenges through practical and data-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting